← Leaderboards
Frederick Matthew Howard
University Of Chicago
$678,980
Attributed
$678,980
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $201.1K · FY2021–25$250K$187.5K$125K$62.5K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$678,980 · 2
By mechanism
K08$603,165 · 1
F32$75,815 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Mary Sara McPeek$6,965,129
- Dezheng Huo$7,892,516
- Olufunmilayo I Olopade$31,360,913
- Brooke E Sylvester$76,838
- Zhen Tian$2,709,652
Others in their field
Other Emerging Leaders on “Malignant Breast Neoplasm”
- Greg Yothers · University Of Chicago$35,003,821
- Olwen Hahn · Brigham And Women'S Hospital$32,076,706
- Leonard Freedman · Leidos Biomedical Research, Inc.$21,750,066
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Leonard Freedmand · Leidos Biomedical Research, Inc.$12,635,631
- Jessica Scott · Sloan-Kettering Inst Can Research$10,553,540
Research focus
Malignant Breast NeoplasmPersonalized MedicineDigital PathologyImagePathologicPathologyDatabasesDigitalGenomic BiomarkerHormone ReceptorMalignant NeoplasmsBiological MarkersChicagoPathologistArtificial IntelligenceCohortBreast Cancer DiagnosisDeep LearningGene ExpressionGene Expression ProfileHematoxylin And Eosin Staining MethodHistologyChemotherapyPredictive Marker
Grant awards (4)
Integrating Clinical, Pathologic, and Immune Features to Predict Breast Cancer Recurrence and Chemotherapy Benefit$201,055
K08 · FY2025 · CA · contact PI
Integrating Clinical, Pathologic, and Immune Features to Predict Breast Cancer Recurrence and Chemotherapy Benefit$201,055
K08 · FY2024 · CA · contact PI
Integrating Clinical, Pathologic, and Immune Features to Predict Breast Cancer Recurrence and Chemotherapy Benefit$201,055
K08 · FY2023 · CA · contact PI
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer$75,815
F32 · FY2021 · CA · contact PI